• 1
    Kelly CM, Dunnett SB, Rosser AE. Medium spiny neurons for transplantation in Huntington's disease. Biochem Soc Trans 2009; 37: 323328.
  • 2
    Bachoud-Lévi AC, Rémy P, Nguyen JP et al. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 2000; 356: 19751979.
  • 3
    Rosser AE, Barker RA, Harrower T et al. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry 2002; 73: 678685.
  • 4
    Gallina P, Paganini M, Lombardini L et al. Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol 2010; 222: 3041.
  • 5
    Björklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci 2000; 3: 537544.
  • 6
    Dunnett SB, Rosser AE. Stem cell transplantation for Huntington's disease. Exp Neurol 2007; 203: 279292.
  • 7
    Park IH, Arora N, Huo H et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877886.
  • 8
    Park IH, Lerou PH, Zhao R et al. Generation of human-induced pluripotent stem cells. Nat Protoc 2008; 3: 11801186.
  • 9
    Kawasaki H, Mizuseki K, Nishikawa S et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 2000; 28: 3140.
  • 10
    Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998; 152: 259277.
  • 11
    Montoya CP, Campbell-Hope LJ, Pemberton KD et al. The “staircase test”: A measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 1991; 36: 219228.
  • 12
    Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res 1970; 24: 485493.
  • 13
    Yan Y, Yang D, Zarnowska ED et al. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 2005; 23: 781790.
  • 14
    Mukhida K, Hong M, Miles GB et al. A multitarget basal ganglia dopaminergic and GABAergic transplantation strategy enhances behavioural recovery in parkinsonian rats. Brain 2008; 131: 21062126.
  • 15
    Kim H, Lee G, Ganat Y et al. miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. Cell Stem Cell 2011; 8: 695706.
  • 16
    Aubry L, Bugi A, Lefort N et al. Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci USA 2008; 105: 1670716712.
  • 17
    Ma L, Hu B, Liu et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid lesioned mice. Cell Stem Cell 2012: 10: 110.
  • 18
    Nakao N, Grasbon-Frodl EM, Widner H et al. DARPP-32-rich zones in grafts of lateral ganglionic eminence govern the extent of functional recovery in skilled paw reaching in an animal model of Huntington's disease. Neuroscience 1996; 74: 959970.
  • 19
    Fricker RA, Barker RA, Fawcett JW et al. A comparative study of preparation techniques for improving the viability of striatal grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplant 1996; 5: 599611.
  • 20
    Li XJ, Li SH, Sharp AH et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995; 378: 398402.
  • 21
    Arrasate M, Finkbeiner S. Protein aggregates in Huntington's disease. Exp Neurol 2011 [Epub ahead of print].
  • 22
    Zhang N, An MC, Montoro D et al. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr 2010; 2:RRN1193.
  • 23
    Camnasio S, Carri AD, Lombardo A et al. The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity. Neurobiol Dis 2012; 46: 4151.
  • 24
    Zou J, Maeder ML, Mali P et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009; 5: 97110.
  • 25
    Benraiss A, Goldman SA. Cellular therapy and induced neuronal replacement for Huntington's disease. 2011; 8: 77590.
  • 26
    Olson SD, Kambal A, Pollock K et al. Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin. Cell Mol Neurosci 2012; 49: 271281.
  • 27
    Olson SD, Pollock K, Kambal A et al. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol 2012: 45; 8798.